Analysts’ Viewpoint on Prostate Cancer Therapeutics Market Scenario
Prostate cancer is the most prevalent non-cutaneous cancer in the world. Globally, the prevalence of prostate cancer is driven by aging population, sedentary lifestyle of the people in industrialized countries, and early onset of urological disorders. Research and development activities aimed at sharpening the focus on "patient-centric" care are anticipated to encourage innovation in the form of efficient medications and treatments in this industry. However, dependence of patients on the availability and coverage of reimbursements from health insurance companies could exert pressure on market participants. The previous 10 years have seen significant advancements in prostate cancer therapies, including enzalutamide, abiraterone acetate, sipuleucel-T, cabazitaxel, and radium-233. Patients have high confidence in androgen-independent prostate cancer medications due to fewer adverse effects, which market participants could use to enhance their production rates. Shifting production facilities to emerging Asia Pacific countries could help market participants lower the prices of prostate cancer treatments.
The global prostate cancer therapeutics market outlook appears positive. Substantial progress has been made in prostate cancer androgen receptor targeting in the past 10 years. The best way to apply immunotherapy and radiopharmaceutical-based treatment in the clinic is yet unknown, but both have made strides. However, the global prostate cancer therapeutics market is likely to be restrained by patients' aversion to expensive cancer therapies and pharmaceuticals. Nevertheless, private and public sector investment in market participants' research and development efforts is projected to propel the global market.
Request a sample to get extensive insights into the Prostate Cancer Therapeutics Market
Reduced morbidity rates in industrialized economies have led to an increase in the elderly population, which is more prone to prostate cancer. According to the Prostate Cancer Foundation, males over the age of 65 account for the majority of prostate cancer cases.
Thus, increase in the geriatric population, sedentary lifestyle of the people in industrialized countries, and rise in obesity at a young age contribute to the global prevalence of prostate cancer. This increases the need of and demand for prostate cancer therapies.
Advanced diagnostic tools have transformed the diagnosis of prostate cancer. Prostate-specific antigen (PSA) level measurement has aided in the identification of prostate cancer. Novel cytotoxic medicines, hormonal drugs, and other anti-prostate-specific membrane antigen treatments are some of the promising new therapeutics in phase II and phase III studies. According to the Mayo Foundation for Medical Education and Research (MFMER), a combination of hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) therapy techniques can induce a targeted immune response against prostate cancers.
Request a custom report on Prostate Cancer Therapeutics Market
In terms of therapy, the global prostate cancer therapeutics market has been classified into hormone therapy, chemotherapy, biologic therapy, and targeted therapy. The hormone therapy segment is anticipated to grow at a rapid pace during the forecast period, as hormone therapy can lessen the chance that cancer will return and stop or slow its growth. Prostate cancer is the fourth most prevalent cancer in both sexes combined, and the second most common cancer in males, according to Globocan. New antiandrogens and luteinizing hormone-releasing hormone antagonists are being introduced in products such as Zytiga and Xtandi.
Large Number of Prostate Cancer Treatments at Hospitals and Simple Reimbursement Procedure to Augment Hospital Pharmacies Segment
Based on distribution channel, the global prostate cancer therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online sales. The hospital pharmacies segment is expected to dominate the global prostate cancer therapeutics market during the forecast period, as large number of prostate cancer treatments are conducted in hospitals and these settings have simple reimbursement procedures.
North America is anticipated to be a highly lucrative market for prostate cancer therapies during the forecast period. This can be ascribed to high cost of newly licensed treatments and rise in disease prevalence in the region. The number of prostate cancer patients is increasing in North America. The U.S.'s large market share and high cost of hormone treatment products are both related. Presence of major companies has increased the number of treatments available in the region.
Europe was the second largest market for prostate cancer therapies in 2021 owing to the high incidence of prostate cancer and rise in awareness about the disease in the region. Growth of the hormone treatment market in Europe can be ascribed to rise in sales of select drugs such as Zytiga and Xtandi. The prostate cancer treatment market in the region is anticipated to be driven by high unmet clinical needs and aging male population. Increase in awareness is also likely to encourage the use of prostate cancer treatments.
Prostate cancer therapies have a sizable market in Asia Pacific. This can be ascribed to the increase in awareness about prostate cancer among patients in the region. Usage of hormone treatment products such as antiandrogens is rising among patients in Asia Pacific, particularly in Japan and China.
The global prostate cancer therapeutics market is fragmented, with the presence of a large number of small-scale players. Key players operating in the global prostate cancer therapeutics market include AbbVie, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Dendreon Pharmaceuticals LLC., Endo Pharmaceuticals, Inc., Ipsen Pharma, Johnson & Johnson Services, Inc., Pfizer, Inc., and Sanofi. These players are adopting growth strategies such as new product development, product launches, product approval, agreement, partnerships, and mergers.
This global market study on prostate cancer therapeutics profiles each of these players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 11.14 Bn |
|
Market Forecast Value in 2031 |
More than US$ 21.7 Bn |
|
Growth Rate (CAGR) 2022-2031 |
6.9% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global prostate cancer therapeutics market was valued at US$ 11.14 Bn in 2021.
The global prostate cancer therapeutics market is projected to reach more than US$ 21.7 Bn by 2031.
The global prostate cancer therapeutics market grew at a CAGR of 5.5% from 2017 to 2021.
The global prostate cancer therapeutics market is anticipated to grow at a CAGR of 6.9% from 2022 to 2031.
Hormone therapy was the leading segment of the global prostate cancer therapeutics market, with 80% share in 2021.
North America is expected to account for the major share of the global prostate cancer therapeutics market during the forecast period.
AbbVie, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Dendreon Pharmaceuticals LLC, Endo Pharmaceuticals, Inc., Ipsen Pharma, Johnson & Johnson Services, Inc., Pfizer Inc., and Sanofi.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Cancer Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Prostate Cancer Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Covid-19 Impact Analysis
6. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Therapy
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy, 2017–2031
6.3.1. Hormone Therapy
6.3.1.1. Luteinizing Hormone-releasing Hormone Analogs
6.3.1.2. Luteinizing Hormone-releasing Hormone Antagonists
6.3.1.3. Antiandrogens
6.3.2. Chemotherapy
6.3.2.1. Systemic Chemotherapy
6.3.2.2. Regional Chemotherapy
6.3.3. Biologic Therapy
6.3.4. Targeted Therapy
6.4. Market Attractiveness Analysis, by Therapy
7. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Sales
7.3.4. Others
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Prostate Cancer Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy, 2017–2031
9.2.1. Hormone Therapy
9.2.1.1. Luteinizing Hormone-releasing Hormone Analogs
9.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists
9.2.1.3. Antiandrogens
9.2.2. Chemotherapy
9.2.2.1. Systemic Chemotherapy
9.2.2.2. Regional Chemotherapy
9.2.3. Biologic Therapy
9.2.4. Targeted Therapy
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Sales
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Prostate Cancer Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy, 2017–2031
10.2.1. Hormone Therapy
10.2.1.1. Luteinizing Hormone-releasing Hormone Analogs
10.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists
10.2.1.3. Antiandrogens
10.2.2. Chemotherapy
10.2.2.1. Systemic Chemotherapy
10.2.2.2. Regional Chemotherapy
10.2.3. Biologic Therapy
10.2.4. Targeted Therapy
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Sales
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Prostate Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy, 2017–2031
11.2.1. Hormone Therapy
11.2.1.1. Luteinizing Hormone-releasing Hormone Analogs
11.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists
11.2.1.3. Antiandrogens
11.2.2. Chemotherapy
11.2.2.1. Systemic Chemotherapy
11.2.2.2. Regional Chemotherapy
11.2.3. Biologic Therapy
11.2.4. Targeted Therapy
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Sales
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Therapy
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Prostate Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy, 2017–2031
12.2.1. Hormone Therapy
12.2.1.1. Luteinizing Hormone-releasing Hormone Analogs
12.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists
12.2.1.3. Antiandrogens
12.2.2. Chemotherapy
12.2.2.1. Systemic Chemotherapy
12.2.2.2. Regional Chemotherapy
12.2.3. Biologic Therapy
12.2.4. Targeted Therapy
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Sales
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Therapy
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Prostate Cancer Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy, 2017–2031
13.2.1. Hormone Therapy
13.2.1.1. Luteinizing Hormone-releasing Hormone Analogs
13.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists
13.2.1.3. Antiandrogens
13.2.2. Chemotherapy
13.2.2.1. Systemic Chemotherapy
13.2.2.2. Regional Chemotherapy
13.2.3. Biologic Therapy
13.2.4. Targeted Therapy
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Sales
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Therapy
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. AbbVie, Inc.
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Business Strategies
14.3.1.5. Recent Developments
14.3.2. Amgen, Inc.
14.3.2.1. Company Overview
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Business Strategies
14.3.2.5. Recent Developments
14.3.3. AstraZeneca
14.3.3.1. Company Overview
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Business Strategies
14.3.3.5. Recent Developments
14.3.4. Bayer AG
14.3.4.1. Company Overview
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Business Strategies
14.3.4.5. Recent Developments
14.3.5. Dendreon Pharmaceuticals LLC
14.3.5.1. Company Overview
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Business Strategies
14.3.5.5. Recent Developments
14.3.6. Endo Pharmaceuticals, Inc.
14.3.6.1. Company Overview
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Business Strategies
14.3.6.5. Recent Developments
14.3.7. Ipsen Pharma
14.3.7.1. Company Overview
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Business Strategies
14.3.7.5. Recent Developments
14.3.8. Johnson & Johnson Services, Inc.
14.3.8.1. Company Overview
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Business Strategies
14.3.8.5. Recent Developments
14.3.9. Pfizer Inc.
14.3.9.1. Company Overview
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Business Strategies
14.3.9.5. Recent Developments
14.3.10. Sanofi
14.3.10.1. Company Overview
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Business Strategies
14.3.10.5. Recent Developments
14.3.11. Other Prominent Players
List of Tables
Table 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 2: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 3: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031
Table 4: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 5: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 6: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 7: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 8: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031
Table 9: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 11: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 12: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 13: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031
Table 14: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 17: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 18: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031
Table 19: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 22: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 23: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031
Table 24: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031
Table 27: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031
Table 28: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy (Therapy), 2017–2031
Table 29: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 30: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, 2017–2032
Figure 2: Global Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 3: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hormone Therapy 2017–2031
Figure 4: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy 2017–2031
Figure 5: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Biologic Therapy 2017–2031
Figure 6: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy 2017–2031
Figure 7: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 8: Global Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 9: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies 2017–2031
Figure 10: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031
Figure 11: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Sales, 2017–2031
Figure 12: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031
Figure 13: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 14: Global Prostate Cancer Therapeutics Market Value Share, by Region, 2017 and 2031
Figure 15: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region, 2022–2031
Figure 16: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 17: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2022–2031
Figure 18: North America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 19: North America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 20: North America Prostate Cancer Therapeutics Market Value Share, by Country, 2017 and 2031
Figure 21: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 22: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 23: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 24: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 25: Europe Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 26: Europe Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 27: Europe Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031
Figure 28: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 20122-2031
Figure 29: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 30: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 31: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031
Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2031
Figure 37: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 38: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 39: Latin America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 40: Latin America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 41: Latin America Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031
Figure 42: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 43: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 44: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 45: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031
Figure 47: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031
Figure 48: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031
Figure 49: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 50: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2031
Figure 51: Global Prostate Cancer Therapeutics Market Share Analysis, by Company, 2021(Estimated)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Prostate Cancer Therapeutics Market
*86 figures and 60 tables includes